Latest News Archives - Slone Partners

Organizational Leader and Business Strategist Kyle Kinzie Named President & Partner, Hospitals & Healthcare Delivery Solutions at Slone Partners

New executive will focus on building out new partnerships in the healthcare delivery sector

SOUTH RIDING, VA. – August 12, 2025 – Slone Partners, a nationwide executive search firm for life sciences and healthcare organizations, has announced that renowned senior executive and organizational leader Kyle Kinzie has joined the company as President & Partner, Hospitals & Healthcare Delivery Solutions.

Kinzie brings more than 20 years of diversified experience scaling and generating profit growth for an array of innovative organizations ranging from startups to Fortune 500 companies. He is recognized as a well-rounded and inspirational cross-functional team leader with an impressive history of expanding the scope and impact of business units in various sectors.

In his new role at Slone Partners, Kinzie will focus on expanding the company’s retained and interim search footprint within the healthcare delivery sector including hospitals, academic health systems, outpatient clinics, and ambulatory care centers. He will further our efforts to build out this industry, leveraging the firm’s strong foundation of client partner relationships and referrals.

“Kyle Kinzie is a remarkably dynamic and innovative strategic leader with a penchant for driving growth across key business verticals – from healthcare to talent management. I’m impressed with his track record and entrepreneurial mindset,” said Slone Partners co-CEO and Managing Partner Leslie Loveless. “He joins our team as we seek out new partnerships and clients to expand our impact in the healthcare delivery space.”

“We are excited to welcome Kyle to Slone Partners as we head toward our second quarter century delivering premier talent to innovative life sciences and healthcare organizations,” said co-CEO and Managing Partner Eric Fink. “Kyle brings an infectious energy and spirit to every project he is involved in, and I see this as a tremendous opportunity for him to scale our healthcare delivery practice at a time when organizations across the healthcare spectrum face increasing pressure to secure passionate and visionary leaders.”

“I’m thrilled to join the outstanding team at Slone Partners,” said Kinzie. “We have an incredible legacy in ife sciences and healthcare, and I’m eager to build on that success by focusing on growth in healthcare delivery—placing visionary leaders in hospitals, health systems, and outpatient organizations. As the industry navigates unprecedented challenges and rapid change, exceptional leadership will be more critical than ever. We have a real opportunity to help organizations strengthen their teams and elevate care across the continuum.”

Prior to joining Slone Partners, Kinzie served as Vice President at Health Carousel, a healthcare staffing and workforce solutions organization. During his four years with Health Carousel, he played a key role in the company’s growth, leading Health Carousel to a #15 ranking in the 2025 Overall US Firms as reported in the Staffing Industry Analysts (SIA) rankings, up from #16 in 2024, while also maintaining the top position as the #1 International Staffing Firm for the third consecutive year.

Kinzie is recognized for his innovative approach to client engagement with extensive experience spanning private equity, public companies, and founder-led ventures. He combines operational excellence and market insight to position organizations for growth, industry influence, and successful outcomes. His past roles include Chief Revenue Officer at Crisp Media Group, SVP at Upswell Marketing, and Vice President and Partner at First Billing.

Kinzie graduated Magna Cum Laude with a Bachelor’s Degree in Marketing and Finance from Miami University.

ABOUT SLONE PARTNERS
Celebrating its 25th year, Slone Partners is a premier executive search and talent advisory firm delivering visionary leaders and fractional talent who build and scale amazing life sciences and healthcare organizations. With a nationwide presence and global reach, we specialize in discovering and placing innovative leaders, including world-class Board, C-Suite, and upper management professionals. To learn more about Slone Partners’ value proposition and our many success stories, visit https://www.slonepartners.com or call 888.784.3422.

« Go Back

Eric Fink Named co-CEO at Slone Partners

Esteemed industry leader will help guide the company’s strategic business planning, operations, and fractional talent service.

SOUTH RIDING, VA. – January 29, 2025 – Slone Partners, a premier executive search and talent advisory firm for life sciences and healthcare organizations, has named Eric Fink as co-CEO and Managing Partner. Fink joined the company in July 2024, initially serving as President and Managing Partner. His professional portfolio includes nearly 25 years of diversified experience building and scaling teams, capabilities, and companies across various functional areas and stages.

Prior to Slone Partners, Fink held several highly successful operational leadership roles at public and private biopharma companies across commercial, human capital, IT, legal, communications, and finance, and counseled executive teams and boards of directors on enterprise-wide strategy, opportunities, and risks.

In his new role at Slone Partners, Fink will work alongside fellow co-CEO Leslie Loveless, helping to guide the company’s strategic business planning and operations, and overseeing its new Fractional Talent service. This service provides current and new clients with access to an extensive network of best-in-class fractional talent comprised of hundreds of verified, seasoned leaders and functional experts.

“Eric is a tremendously talented business strategist who brings significant industry experience and compelling insights to our organization,” said Slone Partners Founder and Chairman Adam Slone. “His efforts to establish Slone Partners as a leader in fractional search are creating new opportunities for our company and our client partners, who are adjusting to shifting market dynamics by forging new hybrid workforce models consisting of both full-time and fractional specialists, expanding capacities at reasonable costs.”

“I am extraordinarily excited to work closely with Eric as we continue to expand both our retained search and fractional search businesses to better meet the talent needs of our clients,” said Slone Partners co-CEO Leslie Loveless. “Eric and I share a passion for fulfilling Slone Partners’ mission of building innovative companies one leader at a time and sustaining important long-term relationships with our clients that further reinforce our unique value proposition. Together, we seek to move our organization forward, leveraging our teams’ many strengths and creating innovative new pathways for success.”

“The opportunity to serve as co-CEO alongside Leslie is one that I eagerly look forward to,” said Fink. “We are aligned on a business plan that scales and expands our range of services while upholding the guiding principles that define our company—transparency, trust, accountability, and a commitment to excellence. With an exceptional team in place, we are confident that Slone Partners will continue to be a leader in the industry and a comprehensive talent partner for our clients in life sciences, healthcare, the nonprofit sector, and beyond.”

Fink earned his Bachelor of Science in Biology from Penn State University and his Master of Science in Organizational Leadership from Mercyhurst University. Loveless graduated cum laude with a Bachelor of Arts in English from Indiana State University and with honors, earning a Master of Arts in English from Butler University.

ABOUT SLONE PARTNERS
Slone Partners is a premier executive search and talent advisory firm delivering visionary leaders and fractional talent who build and scale amazing life sciences and healthcare organizations. With a nationwide presence and global reach, we specialize in discovering and placing innovative leaders, including world-class Board, C-Suite, and upper management professionals. To learn more about Slone Partners’ value proposition and our many success stories, visit https://www.slonepartners.com or call 888.784.3422.

« Go Back

Premier Executive Search and Talent Advisory Firm Slone Partners Launches Fractional Talent Service to Deliver On-Demand Leaders and Specialists

Fractional talent network provides companies access to a deep pool of seasoned consultants

SOUTH RIDING, VA. – October 8, 2024 – Slone Partners, an executive search and talent advisory firm for life sciences and healthcare organizations, is announcing the launch of a fractional talent service. This unique new service line complements the firm’s robust executive search practice, providing current and new clients access to an extensive network of best-in-class fractional talent comprised of hundreds of verified seasoned leaders and functional experts. These professionals are available on-demand to fill important commercial, clinical development, financial, human resources, operations, regulatory, and scientific roles in life sciences, healthcare, nonprofit sectors, and beyond. Click here to join this exceptional network of independent consultants.

The launch of the fractional talent service aligns with the needs of dynamic companies as they seek part-time, interim, and project-based leaders and specialists to support their workloads, business models, and budgets during periods of growth and restructuring.

“With a nationwide presence and global reach, for nearly 25 years Slone Partners has delivered visionary leaders to build and scale amazing life sciences and healthcare organizations,” said Slone Partners CEO and Managing Partner Leslie Loveless. ”As our client partners’ needs evolve, we are excited to launch this new and valuable service for companies that seek fractional leaders and experts on-demand throughout their various business cycles.”

“Fractional talent is a growing need across nearly all sectors, and we view this new service line as a strategic, cost-effective solution for both current and prospective clients looking to strengthen and complement their internal capabilities and build flexibility into their workforce plan,” said Slone Partners President Eric Fink who oversees the company’s fractional talent network and placements. “Our unique fractional talent network serves as the bridge connecting organizations with the experts they need to fill critical gaps and execute project-based work.”

Read more about Slone Partners’ fractional talent services and network on the website: https://www.slonepartners.com/fractional/. Contact Eric Fink at ericf@slonepartners.com to schedule a consultation.

ABOUT SLONE PARTNERS
Founded in 2000, Slone Partners is a premier executive search and talent advisory firm delivering visionary leaders and fractional talent who build and scale amazing life sciences and healthcare organizations. With a nationwide presence and global reach, we specialize in discovering and placing innovative leaders, including world-class Board, C-Suite, and upper management professionals. We complement our search and advisory services with a people and culture consulting practice to help our clients and candidates achieve peak performance and drive business success.

Slone Partners proudly holds the designation as a Certified LGBT Business Enterprise™ by the National Gay & Lesbian Chamber of Commerce (NGLCC) and has earned recognition as a Top Executive Search Firm and a Top 20 Diversity and Inclusion Services firm by Manage HR. To learn more about Slone Partners’ value proposition and our many success stories, visit https://www.slonepartners.com or call 888.784.3422.

« Go Back

Slone Partners Places Jack Kenny on Board of Directors at OraSure Technologies

Respected leader brings more than 30 years of experience in the diagnostics field

SOUTH RIDING, VA. – September 18, 2024 – Slone Partners, a nationwide executive search firm for life sciences and healthcare organizations, has announced the placement of Jack Kenny to the Board of Directors at OraSure Technologies, a leader in point-of-care and home diagnostic tests and sample management solutions.

Kenny is the former Chief Executive Officer for Meridian Bioscience, where he led the company’s turnaround before it was acquired. He has more than 30 years of experience in leadership roles across the in vitro diagnostics, molecular, and lab services industries. Kenny will serve as a Class I Director with an initial term expiring at OraSure’s 2025 Annual Meeting of Stockholders.

Prior to his tenure at Meridian, Kenny served as Senior Vice President and General Manager, North America, with Siemens Healthcare, and as Vice President and General Manager, U.S. Region, for Becton Dickinson, Diagnostic Systems. He also held executive roles at Danaher Corporation and Quest Diagnostics.

“Jack Kenny possesses a broad range of experience in the diagnostics field, having served in roles responsible for acquisition integration, commercial leadership, and product management,” said Kim Wilson, Senior Vice President, Executive Search and Partner at Slone Partners. “He will be a valuable addition to the OraSure Board of Directors as the company continues to increase its investments in innovation and expand its footprint in the market.”

“We recognize the significant industry expertise that Jack will contribute, and we are pleased to continue to strengthen our Board with his participation,” said Mara Aspinall, Chair of the Board of Directors of OraSure. “Under our leadership team led by President and CEO Carrie Eglinton Manner, we have made meaningful progress on our journey to strengthen our foundation, elevate our core growth, and accelerate our profitability. We look forward to the value Jack will add to the company.”

Kenny holds a bachelor’s degree in management from Kettering University.

ABOUT SLONE PARTNERS
Founded in 2000, Slone Partners is a premier executive search firm that delivers visionary leaders who build amazing life sciences and healthcare organizations. With a nationwide presence in the most active industry hubs, we specialize in discovering and placing world-class Board, C-Suite leadership, and upper management talent with experience, conviction, and cultural competence in emerging and well-established companies. Our portfolio of executive search and advisory services includes customized cultural solutions through strategic planning, education, training, and coaching. Slone Partners proudly holds the designation as a Certified LGBT Business Enterprise™ by the National Gay & Lesbian Chamber of Commerce (NGLCC) and has earned recognition as a Top Executive Search Firm and a Top 20 Diversity and Inclusion Services firm by Manage HR. To learn more about Slone Partners’ value proposition and processes, visit https://www.slonepartners.com or call 888.784.3422.

ABOUT ORASURE TECHNOLOGIES
OraSure Technologies, Inc. (“OraSure”) transforms health through actionable insight and powers the shift that connects people to healthcare wherever they are. OraSure improves access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. OraSure, together with its wholly-owned subsidiary, DNA Genotek Inc., is a leader in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. OraSure’s portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, commercial entities, and direct to consumers. For more information on OraSure Technologies, please visit www.orasure.com.

« Go Back

Esteemed Biotech and Biopharma Executive Eric Fink Named President and Managing Partner at Slone Partners

New President will focus on strategic growth opportunities and leveraging technology to enhance business operations and client services

SOUTH RIDING, VA. – July 23, 2024 – Slone Partners, a nationwide executive search firm for life sciences and healthcare organizations, has announced that respected biotech and biopharma executive Eric Fink has joined the company as President and Managing Partner.

Fink brings nearly 25 years of diversified experience building and scaling teams, capabilities, and companies across various functional areas and stages, evolving global life sciences companies from start-up through mid-cap. Throughout his career, Fink has served in several highly successful operational leadership roles across commercial, human capital, IT, legal, communications, and finance, and has counseled executive teams and boards of directors on enterprise-wide strategy, opportunities, and risks.

As President, Fink will oversee Slone Partners’ marketing, finance, human resources, consulting services, and strategic growth areas, including fractional talent placements. He will work alongside Chief Executive Officer and Managing Partner Leslie Loveless and Founder and Chairman Adam Slone to scale the company through new business models and initiatives. Additionally, Fink will collaborate closely with Chief Operating Officer (COO) Alicia Montgomery to enhance the company’s business practices and systems to ensure the most effective, quality-oriented, and efficient client experience.

“Eric Fink is an extremely accomplished industry leader with deep expertise in almost all facets of business operations and growth strategies,” said Loveless. “He joins our leadership team at a pivotal time in our evolution as we expand our line of recruiting and advisory services and integrate AI into our operational infrastructure to enrich the client and candidate experience.”

“I am excited to join the incredible team at Slone Partners. It is clear that we are aligned on a dynamic vision for building upon the company’s remarkable success to date, and I am eager to explore new growth opportunities and enhance our business model efficiencies,” said Fink. “Fractional talent and AI are two key areas where we can significantly enhance our offerings and operations to better serve our client partners in the near term.”

Prior to joining Slone Partners, Fink served as COO of ABio-X Holdings, a private Boston-based investment and incubation company, where he built and scaled the G&A and operating functions of the company and its portfolio companies. Before that, Fink served as Chief Human Resources Officer at Silence Therapeutics; Chief Human Resources Officer at Freeline Therapeutics; Executive Vice President, Chief Human Resources Officer at Global Blood Therapeutics; and in a variety of leadership roles ending as Vice President, Human Resources at Jazz Pharmaceuticals.

Fink earned his B.S. in Biology from Pennsylvania State University and his M.S. in Organizational Leadership from Mercyhurst College.

« Go Back

Respected Executive Recruiting Industry Leader Alicia Montgomery Named Chief Operating Officer at Slone Partners

Promotion reflects the company’s commitment to enhancing its operational capacities and service delivery

SOUTH RIDING, VA. – July 10, 2024 – Slone Partners, a nationwide executive search firm for life sciences and healthcare organizations, has named industry leader Alicia Montgomery as Chief Operating Officer (COO). This strategic move aims to bolster the company’s operational capacities and strengthen its valuable relationships with companies, organizations, and candidates.

Montgomery possesses more than a decade of experience in senior-level recruiting with a successful track record placing high-performing executive leaders across a wide range of functions at innovative medtech and biotech companies. She most recently served as Slone Partners’ Chief Talent Officer. With her impressive background in operational cohesiveness and recruiting, Montgomery excels in resource management, strategic planning, and supporting business growth.

As COO, Montgomery will lead all recruiting operations with a focus on enhancing operational efficiency and automation to support company goals and deliver superior products to clients. She will also work on improving management systems, processes, and best practices within the search execution team.

“Alicia is a committed and passionate leader and team player who has spearheaded the creation of innovative internal talent development strategies as well as successful onboarding and training programs to elevate internal talent,” said Leslie Loveless, Slone Partners Chief Executive Officer and Managing Partner. “As COO, Alicia will continue steering our efforts to build a more robust and efficient work product for our clients, enhancing our national reputation as a premier executive search partner.”

“I am tremendously excited to take on the role of Chief Operating Officer at Slone Partners,” said Montgomery. “This new chapter presents an exciting opportunity to work closely with our leadership team and recruiters to streamline internal operations and enhance our service delivery. My aim is to ensure that we consistently provide a productive and rewarding experience for our clients and candidates.”

Prior to joining Slone Partners, Montgomery worked for more than nine years at Morgan Samuels, where she served as Senior Engagement Director in her last role. In that position, Montgomery led recruiting teams across various client engagements with a focus on client management as well as employee career development. Earlier in her career, Montgomery served as College Recruiter and later as Senior Recruiter at her college alma mater, where she built out student transfer admissions programs, driving market growth and strategy.

Montgomery earned her B.A. in Business Administration from Azusa Pacific University.

ABOUT SLONE PARTNERS

Founded in 2000, Slone Partners is a premier executive search firm that delivers visionary leaders who build amazing life sciences and healthcare organizations. With a nationwide presence in the most active industry hubs, we specialize in discovering and placing world-class Board, C-Suite leadership, and upper management talent with experience, conviction, and cultural competence in emerging and well-established companies. Our portfolio of executive search and advisory services includes customized cultural solutions through strategic planning, education, training, and coaching. Slone Partners proudly holds the designation as a Certified LGBT Business Enterprise™ by the National Gay & Lesbian Chamber of Commerce (NGLCC) and has earned recognition as a Top Executive Search Firm and a Top 20 Diversity and Inclusion Services firm by Manage HR. To learn more about Slone Partners’ value proposition and processes, visit https://www.slonepartners.com or call 888.784.3422.

« Go Back

Slone Partners Places Kurt Gish as Chief Scientific Officer at BioLoomics

Respected Scientific Leader Brings 30 Years of Biotechnology Experience to New Role

SOUTH RIDING, VA. – June 20, 2024 – Slone Partners, a nationwide executive search firm for life sciences and healthcare organizations, has announced the placement of Kurt Gish Ph.D., as Chief Scientific Officer at BioLoomics, a biotechnology company that targets peptide-antibody chimeras to specific compartments inside of diseased cells. Dr Gish will focus on building the company’s pipeline of lysosomal targeting ADCs in oncology to overcome the limitations of poor tumor uptake, which hinders safety and efficacy across the ADC market.

Prior to BioLoomics, Dr. Gish served as Chief Scientific Officer and Founder of Trilo Therapeutics where he pioneered a novel DNA encoded library approach to build D-peptide conjugates to rival traditional ADC modalities. Prior to Trilo, Dr. Gish was an early pioneer in ADCs at AbbVie, investigating novel linkers and payloads, exploring the nature of antigen-independent toxicity and driving two ADC programs into human clinical trials. He serves on the scientific advisory board of the Myeloma Investment Fund of the Multiple Myeloma Research Foundation.

“Kurt Gish is a tremendously talented and highly respected scientist and business leader with a history of driving the development of innovative therapies and treatments,” said Leslie Loveless, CEO and Managing Partner at Slone Partners. “As BioLoomis continues seeking new solutions to unlock the many mysteries of cancer, Dr. Gish will play an important role as part of the company’s leadership team.”

“Kurt is an impressive and accomplished scientist who sits at the intersection of ADCs, peptides, and target discovery/validation. He has a deep understanding of how improper spatial targeting of ADCs has limited the field,” said Doug Chapnick, Founder and CEO of BioLoomis. “With his deep experience in the ADC space, I am confident that Kurt will be invaluable to advancing BioLoomics’s technology to build safer and more efficacious ADCs for both strategic partners and internal programs.”

“BioLoomics is developing incredible technology to deliver more therapeutic drugs directly into cancer cells while minimizing systemic toxicity,” remarked Dr. Gish. “I’m thrilled to join such an innovative team and look forward to getting the best possible treatments to patients who so desperately need them.”

Dr. Gish earned his Ph.D. in Biology from Stanford University and studied molecular immunology during his postdoctoral fellowship at the DNAX Research Institute.

ABOUT BIOLOOMICS
Headquartered in Colorado, BioLoomics is a preclinical stage biotechnology company pioneering directed evolution of antibody-peptide chimeras with programmable cell entry and lysosome targeting. Lysosome targeted antibody-peptide chimeras have broad utility to elicit increased payload delivery mechanisms in the ADC therapeutic space, as well as target degradation in the biologics therapeutic space. The company has raised a total of $10.1 million from top investors including Innovations Endeavors, Horizons Ventures, TechU Ventures, Boom Capital Ventures, BoxOne Ventures, GC&H, and Viswa Colluru.

« Go Back

Slone Partners CEO Leslie Loveless Featured in New Episode of ‘Conversations Life Sciences Leaders Aren’t Having”’ Podcast

Leslie Loveless, CEO and Managing Partner at Slone Partners is featured in a new episode of “Conversations Life Sciences Leaders Aren’t Having,” a podcast hosted by executive coach Jeff Harmon.

The conversation was insightful and spirited, touching on topics ranging from the power of partnerships and her obsession with excellence to the challenges of running a virtual company and the joys of raising an adopted child.

Click here to listen to the full podcast.

« Go Back

Slone Partners Places Kevin Eastwood as Chief Business Officer at Arpeggio Biosciences

Industry veteran brings more than 25 years of experience in senior leadership roles

SOUTH RIDING, VA. – May 29, 2024 – Slone Partners, a nationwide executive search firm for life sciences and healthcare organizations, has announced the placement of Kevin Eastwood as Chief Business Officer at Arpeggio Biosciences, a preclinical therapeutics company whose technology targets transcriptional dysregulation in disease.

Eastwood has more than 25 years of experience in senior leadership roles at innovative pharmaceutical and therapeutics companies across the nation. Most recently he served as Executive Vice President, Corporate Development at Plexium, Inc., where he helped secure a $35M series A-2 financing and $102M series B financing and established two multi-target, multi-year drug discovery collaborations, one with Amgen in the oncology disease area and a second with AbbVie in neuroscience. In prior roles, Eastwood served as Vice President, Corporate Development at the California Institute for Biomedical Research and the Scripps Research Institute; Senior Director, Corporate Development, Gilead Sciences, Inc.; and Startup Founder and Senior Vice President, Corporate Development, Effector Therapeutics, Inc.

“Kevin Eastwood is a highly accomplished and dynamic business leader with extraordinary passion and vision and a track record of success,” said Leslie Loveless, CEO and Managing Partner at Slone Partners. “He brings a high level of strategic management and business development to the outstanding leadership team at Arpeggio.”

“We are thrilled to join forces with Kevin. With over 20 years of experience in business development, at Gilead and platform technology companies like Plexium and Ambrx, Kevin is the ideal person to elevate our functional genomics approach to targeting transcription factors to new heights,” said Joey Azofeifa, CEO at Arpeggio.

“I am grateful for the opportunity to join Arpeggio Biosciences to support its mission to transform the discovery of therapeutics that correct dysregulated transcription,” Eastwood stated. “Arpeggio’s HTS transcriptomics platform GRETA™ provides a novel approach for identifying small molecule transcription modulators, providing an opportunity to drug transcription factors, historically viewed as undruggable targets.”

Eastwood earned his B.S. in biology/chemistry from Missouri State University.

ABOUT SLONE PARTNERS

Founded in 2000, Slone Partners is a premier nationwide executive search firm that delivers visionary leaders who build amazing life sciences and healthcare organizations. With a nationwide presence in the most active industry hubs, we specialize in discovering and placing world-class Board, C-Suite leadership, and upper management talent with experience, conviction, and cultural competence in emerging and well-established companies. Our portfolio of executive search and advisory services includes customized cultural solutions through strategic planning, education, training, and coaching. Slone Partners proudly holds the designation as a Certified LGBT Business Enterprise™ by the National Gay & Lesbian Chamber of Commerce (NGLCC) and has earned recognition as a Top Executive Search Firm and a Top 20 Diversity and Inclusion Services firm by Manage HR. To learn more about Slone Partners’ value proposition and processes, visit https://www.slonepartners.com or call 888.784.3422.

ABOUT ARPEGGIO BIOSCIENCES
Arpeggio Biosciences is drugging transcription factors using AI and rapid RNA-sequencing. Powered by laboratory automation, Arpeggio discovers drugs based on not just a single target, but the entire cellular network. Arpeggio is currently progressing drug programs towards clinical studies in oncology and chronic kidney disease. To learn more, visit www.arpeggiobio.com.

« Go Back

Slone Partners Places Dr. Eugene P. Kennedy as Chief Medical Officer at Carisma Therapeutics

Industry veteran brings expertise in oncology and immuno-oncology and a strong track record of advancing programs through clinical development

SOUTH RIDING, VA. – May 14, 2024 – Slone Partners, a nationwide executive search firm for life sciences and healthcare organizations, has announced the placement of Dr. Eugene P. Kennedy, M.D, F.A.C.S. as Chief Medical Officer at Carisma Therapeutics Inc. (“Carisma”), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies.

Dr. Kennedy brings more than 15 years of clinical and industry experience to Carisma, including cross-functional leadership driving clinical development and regulatory strategies for oncology and immuno-oncology focused organizations. In his role as Chief Medical Officer, he will be responsible for overseeing Carisma’s clinical development, regulatory, and medical affairs functions.

Before joining Carisma, Dr. Kennedy served as Chief Medical Officer at Galera Therapeutics, where he oversaw the development of the company’s radiotherapy in cancer. Prior to that, he served as Chief Medical Officer at Innovative Cellular Therapeutics, where he played a pivotal role in developing the Phase 1 clinical protocol and securing a first-in-human IND for a solid tumor CAR T-cell therapy. Previously, he served as Chief Medical Officer at Lumos Pharma and NewLink Genetics. Earlier in his career, Dr. Kennedy served as Associate Professor of Surgery at Thomas Jefferson University and held various leadership positions at the Jefferson Pancreas, Biliary & Related Cancers Center. Dr. Kennedy has also practiced, taught, and held leadership roles at the Johns Hopkins Hospital and Louisiana State University.

Dr. Kennedy received a bachelor’s degree from the University of Virginia and an M.D. from the Medical College of Virginia.

“Dr. Kennedy is a highly accomplished and respected physician, healthcare executive, and thought leader with extraordinary vision and passion and a history of driving successful new ventures across various therapeutic areas,” said Jennifer Lemasters, Senior Vice President, Executive Search, and Partner at Slone Partners. “He comes to Carisma at an exciting time in its evolution and will be a tremendous addition to its leadership team.”

“On behalf of Carisma, I am delighted to welcome Gene to our team,” said Steven Kelly, President and Chief Executive Officer of Carisma. “With his extensive expertise in oncology and a proven track record in designing and executing clinical trials for solid tumors, Dr. Kennedy brings invaluable insights to our organization that should immediately have a positive impact. We are excited to add his leadership to our organization to build on the momentum in our clinical program and to help advance our pipeline to deliver innovative treatments to patients.”

“Throughout my career, I have always been driven to seek out new modalities with the potential to profoundly impact patients’ lives, and Carisma represents an extraordinary opportunity for me to fulfill this mission,” said Dr. Kennedy.

ABOUT SLONE PARTNERS

ABOUT CARISMA THERAPEUTICS

Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing its proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. Carisma has created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. Carisma is headquartered in Philadelphia, PA. For more information, please visit www.carismatx.com.

ABOUT SLONE PARTNERS

ABOUT CARISMA THERAPEUTICS

Sign up for our Newsletter